Rosenblatt raised the firm’s price target on Imax (IMAX) to $37 from $35 and keeps a Buy rating on the shares. The firm is “pounding the table” on the shares after the company reported another quarter of upside. The shares are not pricing in Imax’s growing market share, the strength of the film slate over the next few years and the potential for additional margin expansion as the box office grows.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAX:
- IMAX Corporation Reports Strong Q2 2025 Results
- IMAX Earnings Call Highlights Record Growth and Optimism
- IMAX’s Strong Market Position and Growth Prospects Justify Buy Rating and Raised Price Target
- Imax price target raised to $32 from $30 at Benchmark
- IMAX Achieves Record Q2 Financial Performance with Strong Box Office Growth